Diabetic nephropathy occurs in approximately one- third of all people with diabetes and is the leading cause of renal failure in developed and developing countries. Angiotensin II plays a potent role in the initiation and progression of diabetic nephropathy by increasing glmoerular pressure and glmoerular selectivity as well as activation of fibrosis and cellular growth in the kidney. Thus, agents which can inhibit the formation of angiotensin – II like ACE inhibitors or agents that can block the action of angiotensin II such as AT1 recptor blockers have potential role in prevention of diabetic nephropathy. This study was designed to evaluate and compare the reno protective effects of (ACEI) perindorpil and (ARB) telmisartan on rats with diabetic nephropathy.
Diabetic nephropathy was induced in rats by streptozotocin (STZ) 100mg/Kg/single I.P administration. Diabetic nephropathy rats were randomly divided into 3 groups. Diabetic nephropathy group, perindopril (6mg/kg/day) and telmisartan group (10mg/kg/day). Each drug was given orally for 8 weeks stating with STZ injection. Fasting blood glucose (FBG) , advanced glycation end products (AGEPs), blood urea, serum creatinine, urine protein, tissue malondyaldehyde (MDA) and tissue reduced glutathione (RG) were measured by colorimetric methods. Renal tissue specimens were histopathologically examined by hematoxylin & eosin staining (H & E).
Both drugs significantly reduced FBG, AGEPs, blood urea, serum creatinine, urine proteins, tissue MDA and significantly increased tissue RG. Moreover, histopahtological examination of kidney tissues showed improvement of nephropathy in the form of reduction of thickening and infiltration of the infalammatory cells with more superior effects of telmisartan over perindopril.
|
